Drug Profile
Dimesna - Lantern Pharma
Alternative Names: BNP 7787; LP 300; TavoceptLatest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator BioNumerik Pharmaceuticals
- Developer BioNumerik Pharmaceuticals; Lantern Pharma
- Class Alkanesulfonates; Antineoplastics; Chemoprotectants; Small molecules; Sulfhydryl compounds
- Mechanism of Action Glutaredoxin modulators; Thioredoxin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Lung cancer
- Phase II Non-small cell lung cancer
- No development reported Peripheral nervous system diseases
Most Recent Events
- 22 Apr 2024 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, Japan (IV)
- 22 Apr 2024 Lantern Pharma receives regulatory approval to initiate the phase II HARMONIC trial in Non-small cell lung cancer in Taiwan and Japan
- 20 Mar 2023 Lantern Pharma has patent protection for dimesna in US, Canada, Brazil, Mexico, EU, China, Japan and Australia